Antares Pharma Inc. (ATRS)

3.35
0.04 1.40
NASDAQ : Health Technology
Prev Close 3.30
Open 3.27
Day Low/High 3.25 / 3.48
52 Wk Low/High 2.53 / 3.96
Volume 1.05M
Avg Volume 1.07M
Exchange NASDAQ
Shares Outstanding 163.06M
Market Cap 539.74M
P/E Ratio N/A
Div & Yield N.A. (N.A)
Additional Dosage Strengths Of Otrexup™ (methotrexate) Injection Approved By FDA

Additional Dosage Strengths Of Otrexup™ (methotrexate) Injection Approved By FDA

Now Available - 12.5 mg/0.4 ml, 17.5 mg/0.4 ml and 22.5 mg/0.4 ml

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Insider Trading Alert - ATRS, CMT And CTIC Traded By Insiders

Stocks with insider trader activity include ATRS, CMT and CTIC

Insider Trading Alert - FLML, WLFC And ATRS Traded By Insiders

Insider Trading Alert - FLML, WLFC And ATRS Traded By Insiders

Stocks with insider trader activity include FLML, WLFC and ATRS

ATRS: Insiders vs. Shorts

ATRS: Insiders vs. Shorts

The most recent short interest data was recently released by the NASDAQ for the 03/01/2016 settlement date, and Antares Pharma Inc. is one of the most shorted stocks of the Russell 3000, based on 19.06 "days to cover" versus the median component at 5.60.

Antares Pharma (ATRS) Stock Lower on Q4 Results

Antares Pharma (ATRS) Stock Lower on Q4 Results

Antares Pharma (ATRS) stock is decreasing on Tuesday morning after the company reported its 2015 fourth quarter results before today’s opening bell.

Antares Pharma Announces CEO Transition

Antares Pharma Announces CEO Transition

Robert Apple Appointed President and Chief Executive Officer

Antares Pharma Announces FDA Approval Of Sumatriptan Injection USP

Antares Pharma Announces FDA Approval Of Sumatriptan Injection USP

Antares' First ANDA Approval of a Therapeutically Equivalent Complex Generic Product

5 Stocks Under $10 Set to Soar

5 Stocks Under $10 Set to Soar

These under-$10 stocks are within range of triggering breakout trades and moving much higher from current levels.

Antares Pharma Announces Update To Quickshot Testosterone Clinical Program

Antares Pharma Announces Update To Quickshot Testosterone Clinical Program

Last Patient Completes Treatment in the Safety and Efficacy Study QST-13-003

Insider Trading Alert - ATRS, SJW And N Traded By Insiders

Insider Trading Alert - ATRS, SJW And N Traded By Insiders

Stocks with insider trader activity include ATRS, SJW and N

Antares Pharma Reports Second Quarter 2015 Operating And Financial Results

Antares Pharma Reports Second Quarter 2015 Operating And Financial Results

Antares Pharma, Inc. (NASDAQ:ATRS) today reported operating and financial results for the second quarter ended June 30, 2015.

Antares Pharma Announces First Patients Enrolled In QuickShot® Testosterone Supplemental Safety Study

Antares Pharma Announces First Patients Enrolled In QuickShot® Testosterone Supplemental Safety Study

Antares Pharma, Inc. (NASDAQ: ATRS) today announced that the first patients have been enrolled in a double-blind, multiple-dose, 26-week safety and pharmacokinetic study of QuickShot ® Testosterone (QS T) administered...

Antares Pharma To Host Second Quarter 2015 Operating And Financial Results Conference Call

Antares Pharma To Host Second Quarter 2015 Operating And Financial Results Conference Call

Antares Pharma, Inc. (NASDAQ: ATRS) today announced it will release its second quarter 2015 financial results before the market opens on Monday, August 10, 2015, and host a webcast and conference call shortly thereafter at...

Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer And Corporate Secretary

Antares Pharma Appoints Peter J. Graham, Esq., Senior Vice President, General Counsel, Human Resources, Chief Compliance Officer And Corporate Secretary

Antares Pharma, Inc. (NASDAQ:ATRS) today announced the appointment of Peter J.

TheStreet Quant Rating: C (Hold)